miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F19%3A00108622" target="_blank" >RIV/00216224:14740/19:00108622 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1158/1538-7445.AM2019-1800" target="_blank" >http://dx.doi.org/10.1158/1538-7445.AM2019-1800</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1158/1538-7445.AM2019-1800" target="_blank" >10.1158/1538-7445.AM2019-1800</a>
Alternative languages
Result language
angličtina
Original language name
miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma
Original language description
Metastatic renal cell carcinoma (mRCC) is routinely treated with sunitinib, a tyrosine kinase inhibitor (TKI) of VEGF signalisation. Although disease eventually progresses in most mRCC patients, length of progression-free survival (PFS) is ranging from few weeks up to more than 24 months. Patients with initial resistance to sunitinib could be redirected to other therapeutical options, as there are several other TKIs available for use in second and third line. However, without a reliable biomarker no result can be predicted. MicroRNAs (miRNAs) belong to class of short non-coding RNAs and could serve as biomarkers of therapy response due to their unique character and presence in tissues and body fluids. Their biomarker potential has been discussed concerning many diseases including mRCC, but current knowledge is very weak, has several discrepancies and is acquired on relatively small cohorts.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/NV18-03-00554" target="_blank" >NV18-03-00554: Molecular classification of renal cell carcinoma based on long non-coding RNAs expression and its implication for diagnosis, prognosis and therapy</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů